WallStSmart

Cosmos Health Inc. (COSM)vsMcKesson Corporation (MCK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 665459% more annual revenue ($397.96B vs $59.79M). MCK leads profitability with a 1.1% profit margin vs -31.0%. MCK earns a higher WallStSmart Score of 57/100 (C).

COSM

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.37

MCK

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 10.0Quality: 7.0
Piotroski: 4/9Altman Z: 5.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

MCKUndervalued (+41.2%)

Margin of Safety

+41.2%

Fair Value

$1622.09

Current Price

$879.75

$742.34 discount

UndervaluedFair: $1622.09Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
37.9%10/10

Revenue surging 37.9% year-over-year

MCK5 strengths · Avg: 9.0/10
Debt/EquityHealth
-6.6410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.2210/10

Safe zone — low bankruptcy risk

Market CapQuality
$108.85B9/10

Large-cap with strong market position

EPS GrowthGrowth
38.0%8/10

Earnings expanding 38.0% YoY

Free Cash FlowQuality
$1.12B8/10

Generating 1.1B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$16.65M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-63.8%2/10

ROE of -63.8% — below average capital efficiency

MCK4 concerns · Avg: 3.3/10
P/E RatioValuation
25.4x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 37.9% demonstrates continued momentum.

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MCK

The primary concerns for MCK are P/E Ratio, Return on Equity, Profit Margin. Thin 1.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while MCK is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.47 — expect wider price swings.

COSM is growing revenue faster at 37.9% — sustainability is the question.

MCK generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

MCK scores higher overall (57/100 vs 41/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Want to dig deeper into these stocks?